Long-term follow-up of people treated with genetically modified T cells
Follows people with blood cancers for up to 15 years after CAR T cell therapy.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Key facts
- Where
- Barcelona, SpainSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received an AUTO CAR T cell therapy in a treatment study. They are followed for up to 15 years after their first infusion.
- Age
- 1 Year and older
- Sex
- All sexes can join.
- Earlier treatment
- Must have received an AUTO CAR T cell therapy in a clinical treatment study.
Main reasons for not taking part
- The record names no specific exclusion criteria.
Read by machine on 9 November 2026.
Where in Spain
- Hospital Vall d'HebronBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Autolus Limited
- Trial code
- NCT03628612
- Record updated
- 22 September 2026
- Original description
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.Read full original descriptionShow less
Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral Vectors
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
Inclusion: Patients must have received an AUTO CAR T cell therapy on a clinical treatment study; Patients must have provided informed consent for long-term follow-up study prior to participation; Patients must be able to comply with the study requirements.
Exclusion: There are no specific exclusion criteria for this study.